A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Latest Information Update: 15 May 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Tomivosertib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms KICKSTART
- Sponsors Effector Therapeutics
- 09 May 2024 According to an eFFECTOR Therapeutics media release, topline results from Phase 2b KICKSTART trial in NSCLC reported in April 2024.
- 29 Apr 2024 Planned End Date changed from 31 May 2024 to 9 Dec 2024.
- 29 Apr 2024 Planned primary completion date changed from 15 Mar 2024 to 14 Oct 2024.